Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders

NCT05086744 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

19

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision

Conditions

Immune Thrombocytopenia (ITP)
Cold Agglutinin Disease (CAD)

Interventions

DRUG: Iptacopan

Sponsor

Novartis Pharmaceuticals